Stephen K. Martin

Affiliations: 
Neuropsychology University of Texas Southwester Medical Center, Dallas, TX, United States 
Google:
"Stephen Martin"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Martin SK, Skidmore LI, Stilwell JD. (2016) A first record of Cretaceous aphids (Hemiptera, Sternorrhyncha, Aphidomorpha) in Australia, from the Lower Cretaceous Koonwarra Fossil Bed, Victoria. Zootaxa. 4137: 95-107
Martin SK, Pu H, Penticuff JC, et al. (2015) Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer. Cancer Research
Martin SK, Farnan JM, McConville JF, et al. (2015) Piloting a Structured Practice Audit to Assess ACGME Milestones in Written Handoff Communication in Internal Medicine. Journal of Graduate Medical Education. 7: 238-41
Martin SK, Kyprianou N. (2015) Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Advances in Cancer Research. 127: 123-58
Cheong CM, Chow AW, Fitter S, et al. (2015) Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research. 332: 24-38
Martin SK, Gan ZY, Fitter S, et al. (2015) The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research. 39: 380-7
Martin SK, Fitter S, Dutta AK, et al. (2015) Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells (Dayton, Ohio). 33: 1359-65
Gan ZY, Fitter S, Vandyke K, et al. (2015) The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology. 94: 343-54
Martin SK, Banuelos CA, Sadar MD, et al. (2014) N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Molecular Oncology
Martin SK, Kamelgarn M, Kyprianou N. (2014) Cytoskeleton targeting value in prostate cancer treatment. American Journal of Clinical and Experimental Urology. 2: 15-26
See more...